It’s also important to read the Spravato label and other paperwork that may come with the drug. The label may have colored stickers that mention an interaction. The paperwork, sometimes called ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

SPRAVATO has been increasing in sales for the ... And then there's an open label, which is a subsequent trial if the patient chooses to enroll in that, then they can go and get one more dose ...

In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were not responsive to two oral ...

That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Ketamine is called a dissociative drug because during a high, which lasts about an hour, people might feel detached from ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

With off-label prescribing, patients have a choice ... In contrast to generic ketamine, Spravato, an intranasal version of ketamine (esketamine), is FDA-approved and therefore is highly regulated.